Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of
directors, determined at the Board of Directors meeting and at the
Audit and Supervisory Committee meeting, following the 148th
Ordinary Meeting of Shareholders, held in Osaka today.
Takeda's Board of Directors has 11 members serving as external
directors out of a total of 14 members, helping to ensure
transparency and objectivity. An external director will continue to
chair the Board of Directors. The Audit and Supervisory Committee,
the Nomination Committee and the Compensation Committee will be
composed solely of external directors including their chairs.
Takeda highly values strong, independent governance and its
Board of Directors helps to ensure that all decisions and actions
are in the best interests of global stakeholders and aligned with
the company’s values. This robust corporate governance model has
been, and will continue to be, critical to Takeda's success.
Details of the new assignments are as follows:
1. New Assignment of Directors Who Are Not Audit and Supervisory
Committee Members (Effective June 26, 2024)
Name
Category
Role
Christophe Weber
Internal
Existing
Representative Director,
President & Chief Executive Officer
Milano Furuta
Internal
New
Director, Chief Financial
Officer
Andrew Plump
Internal
Existing
Director, President, Research
& Development
Masami Iijima
External
Existing
External Director, Chair of the
Board Meeting
Ian Clark
External
Existing
External Director
Steven Gillis
External
Existing
External Director
Emiko Higashi
External
New
External Director
John Maraganore
External
Existing
External Director
Michel Orsinger
External
Existing
External Director
Miki Tsusaka
External
Existing
External Director
2. Directors Who Are Audit and Supervisory Committee Members
(Effective June 26, 2024)
Name
Category
Role
Koji Hatsukawa
External
Existing
External Director, Head of Audit
and Supervisory Committee
Jean-Luc Butel
External
New
External Director, Audit and
Supervisory Committee Member
Yoshiaki Fujimori
External
Existing
External Director, Audit and
Supervisory Committee Member
Kimberly A. Reed
External
Existing
External Director, Audit and
Supervisory Committee Member
3. New Assignment of Nomination Committee and Compensation
Committee Members (Effective June 26, 2024)
Nomination committee: Masami Iijima (Chairperson), Steven
Gillis, Emiko Higashi, Michel Orsinger, Jean-Luc Butel, and
Yoshiaki Fujimori (Observer: Christophe Weber)
Compensation committee: Emiko Higashi (Chairperson), John
Maraganore, Michel Orsinger, and Kimberly A. Reed
About Takeda Takeda is focused on creating better health
for people and a brighter future for the world. We aim to discover
and deliver life-transforming treatments in our core therapeutic
and business areas, including gastrointestinal and inflammation,
rare diseases, plasma-derived therapies, oncology, neuroscience and
vaccines. Together with our partners, we aim to improve the patient
experience and advance a new frontier of treatment options through
our dynamic and diverse pipeline. As a leading values-based,
R&D-driven biopharmaceutical company headquartered in Japan, we
are guided by our commitment to patients, our people and the
planet. Our employees in approximately 80 countries and regions are
driven by our purpose and are grounded in the values that have
defined us for more than two centuries. For more information, visit
www.takeda.com.
Important Notice For the purposes of this notice, “press
release” means this document, any oral presentation, any question
and answer session and any written or oral material discussed or
distributed by Takeda Pharmaceutical Company Limited (“Takeda”)
regarding this press release. This press release (including any
oral briefing and any question-and-answer in connection with it) is
not intended to, and does not constitute, represent or form part of
any offer, invitation or solicitation of any offer to purchase,
otherwise acquire, subscribe for, exchange, sell or otherwise
dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares or other securities are
being offered to the public by means of this press release. No
offering of securities shall be made in the United States except
pursuant to registration under the U.S. Securities Act of 1933, as
amended, or an exemption therefrom. This press release is being
given (together with any further information which may be provided
to the recipient) on the condition that it is for use by the
recipient for information purposes only (and not for the evaluation
of any investment, acquisition, disposal or any other transaction).
Any failure to comply with these restrictions may constitute a
violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns
investments are separate entities. In this press release, “Takeda”
is sometimes used for convenience where references are made to
Takeda and its subsidiaries in general. Likewise, the words “we”,
“us” and “our” are also used to refer to subsidiaries in general or
to those who work for them. These expressions are also used where
no useful purpose is served by identifying the particular company
or companies.
Forward-Looking Statements This press release and any
materials distributed in connection with this press release may
contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of
operations, including estimates, forecasts, targets and plans for
Takeda. Without limitation, forward-looking statements often
include words such as “targets”, “plans”, “believes”, “hopes”,
“continues”, “expects”, “aims”, “intends”, “ensures”, “will”,
“may”, “should”, “would”, “could”, “anticipates”, “estimates”,
“projects”, “forecasts”, “outlook” or similar expressions or the
negative thereof. These forward-looking statements are based on
assumptions about many important factors, including the following,
which could cause actual results to differ materially from those
expressed or implied by the forward-looking statements: the
economic circumstances surrounding Takeda’s global business,
including general economic conditions in Japan and the United
States; competitive pressures and developments; changes to
applicable laws and regulations; challenges inherent in new product
development, including uncertainty of clinical success and
decisions of regulatory authorities and the timing thereof;
uncertainty of commercial success for new and existing products;
manufacturing difficulties or delays; fluctuations in interest and
currency exchange rates; claims or concerns regarding the safety or
efficacy of marketed products or product candidates; the impact of
health crises, like the novel coronavirus pandemic; the success of
our environmental sustainability efforts, in enabling us to reduce
our greenhouse gas emissions or meet our other environmental goals;
the extent to which our efforts to increase efficiency,
productivity or cost-savings, such as the integration of digital
technologies, including artificial intelligence, in our business or
other initiatives to restructure our operations will lead to the
expected benefits; and other factors identified in Takeda’s most
recent Annual Report on Form 20-F and Takeda’s other reports filed
with the U.S. Securities and Exchange Commission, available on
Takeda’s website at:
https://www.takeda.com/investors/sec-filings-and-security-reports/
or at www.sec.gov. Takeda does not undertake to update any of the
forward-looking statements contained in this press release or any
other forward-looking statements it may make, except as required by
law or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this
press release may not be indicative of, and are not an estimate,
forecast, guarantee or projection of Takeda’s future results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240619545549/en/
Media Contacts: Japanese Media Shoko Honda
shoko.honda@takeda.com +81 (0) 70-2687-3620
U.S. and International Media Brendan Jennings
brendan.jennings@takeda.com +81 (0) 80-2705-8259
Takeda Pharmaceutical (NYSE:TAK)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Takeda Pharmaceutical (NYSE:TAK)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024